他克莫司治疗鸟枪弹样视网膜脉络膜炎的安全性与疗效:回顾性病例系列综述
在英国Moorfields眼科医院葡萄膜炎专科,回顾性分析25例接受他克莫司治疗的鸟枪弹样视网膜脉络膜炎(BRC)患者;21例(84%)耐受良好,4例需停药,肾功能无重大变化,泼尼松龙日均剂量由19.7 mg降至6.9 mg(t=5.071,p=0.001),视野与视觉功能稳定或改善。
要点
- 25例BRC患者中21例(84%)对他克莫司耐受良好,4例因故停药。
- 泼尼松龙日均剂量由研究开始时19.7 mg降至结束时6.9 mg(t=5.071,p=0.001)。
- 视野平均偏差改善:右眼1.8±2.4 dB(t=3.821,p=0.004),左眼1.9±2.7 dB(t=3.06,p=0.007)。
核心结论
- 作者认为,他克莫司作为二线药物长期用于BRC患者具有良好的安全性,可减少激素用量并使视觉功能稳定或改善。
研究设计与样本
- 回顾性病例系列综述,纳入Moorfields眼科医院葡萄膜炎专科诊断为BRC并接受他克莫司治疗的25例患者的病历资料(平均年龄50.4±10.8岁)。
- 主要结局指标为安全性(副作用)与疗效(炎症控制,以及至少6个月及1年时以Humphrey视野和电生理检查评估的视觉功能)。
主要发现
- 25例中21例(84%)对他克莫司耐受良好,4例需停用他克莫司。
- 无患者出现肾功能重大变化:治疗第1个月末3/21例(14.28%)肾功能轻度异常(低于30%),3个月时1/21例(4.76%),6个月治疗期末仅1/21例(4.76%)肾功能轻度异常。
- 泼尼松龙日均剂量由研究开始时19.7 mg降至结束时6.9 mg(t=5.071,p=0.001)。
- 视力大多保持稳定;视野随时间改善:Humphrey平均偏差右眼平均改善1.8±2.4 dB(t=3.821,p=0.004),左眼1.9±2.7 dB(t=3.06,p=0.007)。
- 电生理功能在10例中改善;4例初始功能恶化者在调整他克莫司剂量后改善。
临床怎么用
- 作者认为,他克莫司可作为BRC的二线药物长期使用,具有良好安全性,可减少激素用量并使视觉功能稳定或改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Evaluation of the use of tacrolimus in the treatment of birdshot retinochoroiditis (BRC) at a tertiary referral centre with the aim to describe its safety and efficacy. METHODS: The medical records of 25 patients diagnosed with BRC at uveitis service, Moorfields Eye Hospital, and who had received tacrolimus treatment were retrospectively reviewed. The main outcome measures of the study were (1) safety of tacrolimus in terms of side effects and (2) efficacy, as measured both by control of inflammation and visual function assessed by Humphrey visual fields and electrophysiological testing over at least 6 months and then 1 year. RESULTS: Tacrolimus was commenced in 25 patients (mean age 50.4±10.8 years) and was well tolerated in 21 patients (84%). It was necessary to stop the tacrolimus in four patients. No patient showed major changes in renal function: 3/21 patients (14.28%) showed slightly abnormal (less than 30%) function at the end of the first month of treatment; 1/21 (4.76%) patients at 3 months, but at the end of a 6-month treatment period only 1/21 patients (4.76%) showed minor abnormality in renal function. The mean daily prednisolone dose was 19.7 mg at the beginning of the study, which had fallen to 6.9 mg at the end (t=5.071, p=0.001). Visual acuity mostly remained stable. Visual fields improved over time (mean improvement in Humphrey mean deviation, right eye=1.8±2.4 dB, t=3.821, p=0.004; left eye=1.9±2.7, dB, t=3.06, p=0.007). Electrophysiological function showed improvement in 10 patients, and in four patients an initial deterioration in function improved following tacrolimus dose adjustment. CONCLUSION: Tacrolimus has a good safety profile for long-term use in patients with BRC as a second-line agent enabling steroid sparing and visual function stabilisation or improvement.
引用
- Islam F, Westcott M, Rees A, et al. Safety profile and efficacy of tacrolimus in the treatment of birdshot retinochoroiditis: a retrospective case series review. Br J Ophthalmol. 2017. PMID: 29051329. doi:10.1136/bjophthalmol-2017-310436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。